Equities Analysts Offer Predictions for ZVRA Q1 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at Roth Capital boosted their Q1 2025 earnings per share estimates for shares of Zevra Therapeutics in a research note issued to investors on Sunday, February 9th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of ($0.27) for the quarter, up from their prior forecast of ($0.30). The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics' Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at ($0.17) EPS, FY2026 earnings at $0.82 EPS, FY2027 earnings at $1.53 EPS and FY2028 earnings at $1.97 EPS.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. During the same quarter last year, the business posted ($0.40) EPS.

ZVRA has been the subject of a number of other research reports. Cantor Fitzgerald upgraded Zevra Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 29th. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Finally, Canaccord Genuity Group decreased their target price on Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, November 14th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $21.57.

Zevra Therapeutics Stock Up 1.0 %

Shares of ZVRA stock traded up $0.08 during trading hours on Wednesday, reaching $8.07. The company had a trading volume of 348,570 shares, compared to its average volume of 389,933. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a market capitalization of $430.78 million, a P/E ratio of -4.10 and a beta of 2.00. The stock's fifty day simple moving average is $8.22 and its 200 day simple moving average is $8.04.

Hedge Funds Weigh In On Zevra Therapeutics

A number of hedge funds have recently modified their holdings of ZVRA. International Assets Investment Management LLC grew its holdings in shares of Zevra Therapeutics by 594.0% in the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after acquiring an additional 5,940 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after acquiring an additional 2,452 shares during the last quarter. Hunter Associates Investment Management LLC acquired a new position in shares of Zevra Therapeutics in the 3rd quarter worth $92,000. XTX Topco Ltd acquired a new position in shares of Zevra Therapeutics in the 3rd quarter worth $94,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Zevra Therapeutics during the fourth quarter valued at $94,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zevra Therapeutics

In other news, EVP Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now directly owns 29,486 shares in the company, valued at approximately $231,759.96. This trade represents a 26.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the transaction, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 85,773 shares of company stock valued at $674,176 in the last quarter. Corporate insiders own 2.40% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.